RBC Capital Markets keeps an 'outperform' rating on AstraZeneca with a target price of 14,500p, expecting solid Q3 revenue and earnings ahead of results due October 30. Oncology sales, led by lung cancer drug Tagrisso, are forecast above consensus, while diabetes drug Farxiga faces declines post-patent loss. The AVANZAR trial for lung cancer treatment remains a key catalyst, with RBC anticipating management to confirm full-year growth guidance. The target price reflects confidence in AstraZeneca's drug pipeline and expected earnings growth.
AstraZeneca shares are trading at USD 168.52 on Pluang as of Oct 15, 2026 21:51 WIB, showing a 4.01% gain in the past day. The stock's market cap stands at $252.85 billion, reflecting strong investor interest. Buy orders currently make up 59% of Pluang's activity, indicating a positive sentiment among users.
